Background
==========

Copper serves as a cofactor for a number of oxygen-processing enzymes involved in diverse metabolic processes, but the metal is highly toxic as a free ion. Upon entering the cell the copper is bound to a number of copper chelating transporters (copper chaperones), which guide the copper ion to different cellular locations while protecting the cellular environment from the toxic effect of copper. Copper chaperones are highly specific for their targets and they participate directly in the loading of the metal into the recipient molecule. One of the copper chaperones is CCS (Copper Chaperone for SOD), which targets copper to Cu, Zn-superoxide dismutase (SOD1) \[[@B1]\].

Superoxide dismutases are the major antioxidant enzymes involved in free radical scavenging. These enzymes exist in three distinct forms, where two of them contain copper (SOD1 and SOD3), and the third one contains manganese (SOD2). SOD1 (Cu, Zn-superoxide dismutase) is located in the cytoplasm and peroxisomes, and the metal is inserted into the enzyme in the cytosol by means of the chaperone CCS after the enzyme has been synthesized \[[@B1]\].

The *CCS* gene has been localized to 11q13 and three functional domains have been described in the 274 amino acid long protein product \[[@B2],[@B3]\]. Domain I (1--85) is the copper binding site with the consensus MTCXXC motif that is conserved in several other copper binding proteins including HAH1, ATP7A/ATP7B and SOD1. This domain is important in scavenging Cu from the cells and accepting the metal from the transporters. Domain II (86--234) has sequence homology to the SOD1 domain, which is associated with Cu and Zn binding. Domain III (235--274) contains a CXC motif, which is a copper site essential for CCS-SOD1 transmetalation reaction. CCS interacts with SOD1 by two putative metal binding sites at the opposite ends via domains I and III \[[@B4]\]. It has been shown that copper chaperone CCS can interact both with the wild type and the SOD1 mutant in amyotrophic lateral sclerosis (ALS) \[[@B5]\].

ALS is a progressive fatal disorder, which results from the degeneration of motor neurons in the brain and spinal cord. ALS is one of the most common adult-onset neurodegenerative disorders, leading to death within 2--5 years of clinical onset. Approximately 10% of ALS patients are familial cases and approximately 15--20% of these familial cases is associated with mutations in the *SOD1* gene \[[@B6]-[@B8]\]. Recently, homozygous mutations have been described in the *alsin* gene, located at 2q33, and a new locus has been proposed in a 8-Mb region on chromosome 18q21 in different families with various forms of FALS \[[@B9]-[@B12]\]. In sporadic cases of ALS de novo mutations in the *SOD1* gene has only occasionally been observed \[[@B13]-[@B15]\]. Apparent heterogeneous distribution of ALS patients with *SOD1* gene mutations among different populations suggests that other genetic loci should be involved in the disease.

In brain CCS and SOD1 co-localize within the same cell types \[[@B15]\] and SOD1 can not acquire its Cu in the absence of the CCS \[[@B16]\]. Due to its biological function we have considered *CCS* as a potential candidate gene for ALS. Herein we report the exon/intron structure of the human *CCS* and the mutational analysis of the entire coding region of the gene in 20 individuals affected with ALS.

Results and discussion
======================

Genomic organization of *CCS*
-----------------------------

The genomic sequence of the *CCS* was obtained from the sequence information of unordered fragments of two BAC clones RP11-527H7 (AC019220.3) and CMB9-75A11 (AP000481) which were identified through a BLAST <http://www.ncbi.nlm.nih.gov:80/blast/> search of the NCBI High-Throughput Genomic Sequences (HTGS) Database using the cDNA sequence of the *CCS* gene (accession no: AF002210). Correct orientation of the sequence and the final order of the gene elements, coding and non-coding regions were assembled by alignment of the *CCS* cDNA sequence with genomic sequences. Exon-intron boundaries were established by the identification of the conserved splice site consensus sequences (table [1](#T1){ref-type="table"}) and the results were verified by sequencing exon-intron boundaries using genomic DNA and intron specific primers placed within at least 25 bp away from the exons (table [2](#T2){ref-type="table"}).

###### 

Exon intron structure of the *CCS* gene

  **Exon**   **Exon Size (bp)**   **3\' Splice acceptor**   **5\' Splice donor**    **Intron size (kb)**   **Nucleotide position**   **AA position**   
  ---------- -------------------- ------------------------- ----------------------- ---------------------- ------------------------- ----------------- ------------
  1          82                                             GCACG**gt**gagggtcgag   0.341                  1 -- 82                   1 -- 13           domain I
  2          73                   ccgcccttgc**ag**TTGGA     GGCAG**gt**aagaacaggg   5.402                  83 -- 135                 14 -- 37          
  3          138                  ctttcttgcc**ag**GTGTC     GTTGC**gt**gagtgaccac   0.205                  136 -- 273                38 -- 83          
                                                                                                                                                       
  4          178                  aataccttgc**ag**AGAAT     AACAG**gt**gagttgtctg   0.852                  274 -- 451                84 -- 143         domain II
  5          61                   tttctttctt**ag**CTGTG     ACCGG**gt**aagtgtctgt   4.786                  452 -- 512                144 -- 163        
  6          77                   atctcattcc**ag**CACCG     TGAAG**gt**aaggtggaaa   0.072                  513 -- 589                164 -- 189        
  7          102                  ctcccctcaa**ag**GTGTG     GAGAG**gt**gagtggtgtc   0.109                  590 -- 691                190 -- 224        
                                                                                                                                                       
  8          318                  attcttctgc**ag**GTTGG                                                    692 -- 1009               225 -- 274        domain III

###### 

Primers and PCR conditions used for analysis of *CCS* gene

  **Exon**   **Forward**            **Reverse**            **Product Size (bp)**   **Annealing Temp (°C)^\*^**
  ---------- ---------------------- ---------------------- ----------------------- -----------------------------
  **1**      CGCCGCGCTGGTTGGTG      CGGCGAGGCTCCACACGAAG   138                     57
  **2**      CGATCATCGGTTGGT        TAATAGATTCGCCTGGTC     173                     51
  **3**      CAGCCTCTGTTGCCCTCT     ACCTTCCTCAAAGCCACTCC   285                     57
  **4**      CAAGCCAGCCCAAGTGTCTA   TGAGGGCCCAGTGTGAAA     271                     57
  **5**      CCTGTGAGCTGCTTTCCT     TCTGAGACTTTGGGTCCTCT   159                     57
  **6**      ATAGCAGCTTGGCACCAC     GATGATGGACCCTGTTAGGA   184                     57
  **7**      TGGGCACCCTTCCTAACAG    ACCATCCGCAGAGCACAG     201                     57
  **8**      CACCCCTGACCACACATT     ATAAGGGGCATGGAGACAA    379                     57

^\*^PCR conditions: initial denaturation at 94°C for 5 min; 40 cycles of denaturation at 94°C (30 s), annealing (30 s), extention at 72°C (40 s); final extension at 72°C for 7 min.

The 823 bp translated region of the *CCS* gene was organized in 8 exons and from the translation start site to the translation termination site it spans 12798 bp of genomic DNA (table [1](#T1){ref-type="table"}). ATG translation start codon was in the 43 bp exon 1. The smallest exon was the 61 bp exon 5, while the largest exon was the last exon (exon 8) which contained the 150 bp translated sequence, TGA translation termination site, 163 bp 3\'-untranslated sequence and a polyadenylation site. The splice donor and acceptor sites in all exons conformed to the AG/GT rule \[[@B18],[@B19]\]. The sizes of the introns were determined from the published sequences of the two BAC clones (Table [1](#T1){ref-type="table"}). The smallest intron was the 72-bp intron 6 and the largest was intron 2, which was 5402 bp long. All introns were type 0 (uninterrupted codon).

Database analysis <http://www.friutfly.org/cgi-bin/seq_tools/promoter.pl> predicted two transcription start sites at -300 to -250 bp and -1606 to -1565 bp within 1713 bp of genomic sequence upstream to the translation initiation codon. In order to roughly determine the extent of the 5\' untranslated region of the *CCS* gene, a series of RT-PCRs have been performed using 7 different forward primers residing within a sequence of 1670 bp upstream to the ATG start codon (starting at nucleotide positions -1672, -1442, -871, -603, -302, -214 and -38, respectively) -38, respectively) and the same reverse primer (5\'-CGTGCAGAGGGTCCC-3\', starting from nucleotide position +22 of the *CCS* gene) downstream to the start codon. In these reactions cDNA synthesized from human heart was used and genomic DNA served as control. These analyses suggested a transcription start site between nucleotides 588 and 302 upstream to the start codon. In the meanwhile, the results also suggested presence of another gene in the opposite direction.

600 bp region upstream to the translation start site of CCS gene was analyzed for presence of transcription factor binding sites using Genomatics Genomatics MatInspector Professional program <http://www.genomatics.de>. Sites for activator protein, zinc finger interaction domain, E-box binding factor, X-box binding factor, myeloid zinc finger 1 factor, myeloblast determining factor and winged helix protein binding site have been detected within 430 bp in the 5\' region of the gene with 100% core similarity and 95% matrix similarity.

Mutation analysis of *CCS* in ALS patients
------------------------------------------

The entire protein-coding region of *CCS* was screened for mutations in 20 ALS patients. In exon 8 a silent mutation (847G\>A) was detected in five Danish patients, where one patient was homozygous and four were heterozygous. Further screening of 25 Danish individuals revealed this SNP in 9 chromosomes. The 847G\>A transition was also predicted as a candidate SNP by statistical analysis of human expressed sequence tags \[[@B20]\] and reported in the NCBI, Single Nucleotide Polymorphism database (ID 58140, <http://www.ncbi.nlm.nih.gov/SNP/>). The frequency of this polymorphism in the Danish population analyzed in the present study was calculated as 0.19 (15/80 independent chromosomes). Statistical analysis by Fishers test showed no significant difference between this value and the previously predicted frequency (LeeLab SNP database, <http://www.bioinformatics.ucla.edu/snp/>). In the NCBI SNP Database there were two other predicted SNPs within exon 8 of *CCS* (ID 55000 and 57614), those SNPs were not detected among the 90 chromosomes analyzed in the present study.

Conclusions
===========

Sporadic patients comprise the majority of ALS cases (90 %) and the underlying genetic component is known in only a small number of sporadic cases. Codon deletions or insertion in the KSP repeat motif of the neurofilament *NF-H* gene has been identified in \~1% of the sporadic ALS cases \[[@B21]\]. Segregation of DNA markers flanking the *CCS* gene was previously investigated in two FALS families but no evidence of linkage was shown in these two families \[[@B22]\]. Very recently the role of CCS in FALS has been studied by ablating the *CCS* gene in FALS-linked SOD1-mutant mice. Although the absence of CCS led to a significant reduction in the amount of copper loaded mutant-SOD1, it did not modify the onset and progression of the disease in FALS-linked SOD1-mutant mice \[[@B23]\]. In the present study, we could not detect any disease causing mutations in *CCS* among 20 sporadic ALS patients we have analyzed. The genomic organization of the *CCS* gene and the intragenic SNP described in this study can be used in investigating further ALS patients/families.

Materials and methods
=====================

20 sporadic cases of ALS (5 Greek and 15 Danish patients) were investigated. The patient cohort was composed of 8 females and 12 males aged from 46 to 84. All the cases met the criteria for ALS with both upper and lower motor neuron involvement. The patients did not have any mutations in the SOD1 gene.

Exons of the *CCS* gene were PCR amplified using intron specific primers and 20 ng genomic DNA (table [2](#T2){ref-type="table"}). PCR was performed in a 15 μl reaction mixture containing 2.5 mM each dNTP, 12 pmol each primer, 0.1 U *Taq* DNA polymerase (Amersham Life Science Inc.), 1 × reaction buffer in a thermal cycler (MJ Research). For PCR conditions see table [2](#T2){ref-type="table"}. Amplification products were gel purified and sequencing was performed on both strands with the same amplification primers using Thermo Sequenase Radiolabelled Terminator Cycle Sequencing kit (Amersham Life Science Inc.) in a thermal cycler (MJ research).

The single nucleotide polymorphism (SNP) in exon 8 (847G\>A), which destroyed a Fnu4HI recognition site was screened in 25 healthy unrelated Danes using a PCR induced restriction site assay. Following PCR amplification of exon 8 (table [2](#T2){ref-type="table"}), the 384 bp-PCR product was digested with Fnu4H (New England Biolabs) producing 302 bp and 82 bp fragments in the 847G allele, and 165 bp, 137 bp and 82 bp fragments in the 847A allele. The fragments separated on a 2% agarose gel were visualized by ethidium bromide staining.
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